4 activators of Vitamin D for Prostate Cancer

VDR Activators

Pereplexity AI - Deep Research

Yes — several VDR activators from the list are well-suited for prostate cancer, but the biology here is more nuanced than for CRC. The key complication is that the androgen receptor (AR) actively suppresses VDR expression in prostate cancer cells, so agents that simultaneously attack AR signaling and boost VDR activity are doubly valuable. pubmed.ncbi.nlm.nih

The top candidates with prostate-specific evidence are:

  • Curcumin — binds VDR directly and suppresses AR transactivation/protein levels; works in both androgen-sensitive and castration-resistant lines pmc.ncbi.nlm.nih
  • Sulforaphane — inhibits HDAC6, destabilizing the HSP90 chaperone that AR requires, causing AR protein degradation and reducing PSA and TMPRSS2:ERG expression pdfs.semanticscholar
  • Berberine — suppresses AR signaling and degrades AR protein; also inhibits AKR1C3, an enzyme driving intratumoral androgen synthesis in castration-resistant prostate cancer (CRPC) pmc.ncbi.nlm.nih
  • Butyrate — synergizes with vitamin D analogs to restore VDR-mediated apoptosis in prostate cancer cells by reversing HDAC-based silencing of VDR experts.arizona
  • Resveratrol — potentiates VDR-RXR heterodimerization and SIRT1-mediated nuclear receptor deacetylation, amplifying VDR signaling pubmed.ncbi.nlm.nih

Two important warnings specific to prostate cancer:- Omega-3: The CAPFISH-3 trial (2025) showed fish oil + high omega-3/low omega-6 diet reduced prostate Ki-67 by 15% in active surveillance, but high plasma omega-3 levels were associated with a 43% increased prostate cancer risk in the SELECT cohort — so lowering omega-6 simultaneously appears critical pmc.ncbi.nlm.nih- Zinc: Low-dose post-diagnosis zinc (1–24 mg/day) was linked to a 45% lower lethal prostate cancer risk, but high-dose zinc (>75–100 mg/day) may substantially increase aggressive cancer risk mayoclinic.elsevierpure

The report covers all compounds with a detailed comparison table, the AR-VDR antagonism mechanism, and the TMPRSS2:ERG complication.